Curasight A/S approved for listing at Spotlight Stock Market
Curasight is built on more than a decade of research at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Over the last several years Professor Andreas Kjaer has together with a scientific team developed the concept of PET imaging of the receptor (uPAR), a known biomarker of cancer aggressiveness, to be used for improved diagnosis, risk stratification and treatment planning/ monitoring in multiple types of cancer.
Curasight A/S, is a danish biotech company registered in 2013 with focus on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET imaging ligand, uTRACE® (radioactive tracer), targeting the receptor uPAR. uPAR is expressed in many types of human cancers and the expression levels of uPAR have been shown to be strongly associated with metastatic disease, i.e. cancer aggressiveness, and subsequent poor prognosis. Curasight’s clinical PET ligand uTRACE® has been extensively validated in several clinical PET imaging trials including a first-in-humans phase I/IIa clinical trial with uTRACE® in prostate, breast and urinary bladder cancer and two completed and one ongoing phase IIb clinical trials in breast, prostate and brain with promising results.
Based on these promising results, combined with the strong biomarker potential of uPAR in human cancer, Curasight’s Board and management projects that uTRACE® could become a successful clinical uPAR-PET imaging ligand provided further positive results in future studies. Such a PET ligand could become a game-changer in the management of cancer patients.
” With an array of positive results from the clinical imaging studies and further Proof-of-Concept results for therapy in preclinical studies, Curasight’s Board and management believe the Company is an attractive candidate for partnership or out-licensing agreement with Big Pharma. We kindly invite you to participate in Curasight’s capitalization and future development.”
- CEO Ulrich Krasilnikoff & CSO Prof. Andreas Kjaer, Curasight A/S
Offer
In order to further advance and commercialize the uPAR Theranostics platform with uTRACE® for improved diagnosis and treatment across several cancer diseases, including brain, prostate, pancreatic and breast cancer. Curasight is now planning to conduct an issue of units (shares and free-of-charge warrants). The offer comprises of a maximum of 2,270,000 shares and a maximum of 1,986,250 warrants of series TO 1, corresponding to initially approximately DKK 32,7 million and at a later stage DKK 34.2 million, respectively. If the issue is fully subscribed and all associated warrants are exercised, Curasight will receive a capital injection totalling approximately DKK 66.9 million before issuance costs. The subscription period starts on Thursday, the 3rd of September 2020, and ends on the 17th of September 2020. The valuation (pre-money) calculates to approximately DKK 200 million.
Listing at Spotlight Stock Market
Curasight A/S has been approved for listing at Spotlight Stock Market. The first day of trading is planned to October 8, 2020. The approval is given under the condition that the company raises the minimum limit and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming IPO.
Information about the share
Short name: CURAS
ISIN: DK0061295797
First day of trading: October 8, 2020
Information about the warrants
Short name: CURAS TO 1
ISIN: DK0061408747
First day of trading: October 8, 2020
The company prospectus will shortly be published at www.spotlightstockmarket.com
For more information, please contact:
Oskar Wollert
Head of Listing, Spotlight Stock Market
+46 8 511 68 008